Bharat Biotech stresses on Covaxins safety record after AstraZeneca admits to Covishield causing rare cl – The Times of India

HYDERABAD: After AstraZenecas admitted in a UK court that its Covid-19 vaccine caused a rare side-effect Thrombosis with Thrombocytopenia Syndrome (TTS), Hyderabad-based vaccine maker Bharat Biotech on Thursday stressed on the safety of its indigenous vaccine Covaxin to allay public concerns over Covid vaccines. AstraZenecas vaccine Vaxzevria, which it developed in collaboration with Oxford University, was manufactured under the Covishield brandname in India by Pune-based Serum Institute of India (SII). Bharat Biotech developed the inactivated whole virion vaccine Covaxin. Both of them were the most widely administered vaccines under Indias Covid-19 vaccine immunisation drive.

Expand

Expand

Read more here:

Bharat Biotech stresses on Covaxins safety record after AstraZeneca admits to Covishield causing rare cl - The Times of India